BUPROPION AS A MODULATOR OF DRUG ACTIVITY
Disclosed herein are methods of treating neurological or psychiatric diseases or disorders using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.
1 . (canceled)
2 . A method of treating depression comprising: orally administering a dosage form daily to a human being suffering from depression; wherein the dosage form comprises dextromethorphan or a pharmaceutically acceptable salt thereof, and venlafaxine or a pharmaceutically acceptable salt thereof; wherein the dextromethorphan and the venlafaxine are the only therapeutically active agents in the dosage form; and wherein the human being is an extensive metabolizer of dextromethorphan.
3 . The method of claim 1 , wherein the dosage form is orally administered for at least 8 consecutive days.
4 . The method of claim 1 , wherein the depression is major depressive disorder.
5 . The method of claim 1 , wherein the depression is treatment resistant depression.
6 . The method of claim 1 , wherein the dosage form comprises about 30 mg to about 150 mg of the venlafaxine.
7 . The method of claim 1 , wherein the dosage form is orally administered for at least 14 consecutive days.
8 . The method of claim 1 , wherein the dosage form provides immediate release of the dextromethorphan.
9 . The method of claim 1 , wherein the dosage form provides sustained release of the Desvenlafaxine.
10 . The method of claim 1 , wherein the dosage form contains about 20 mg to about 50 mg of the dextromethorphan.
11 . The method of claim 1 , wherein the dosage form contains about 30 mg to about 60 mg of the dextromethorphan.
12 . The method of claim 1 , wherein the dosage form contains about 40 mg to about 50 mg of the dextromethorphan.
13 . The method of claim 1 , wherein the dosage form contains about 50 mg to about 70 mg of the dextromethorphan.
14 . The method of claim 1 , wherein the dosage form contains about 70 mg to about 100 mg of the dextromethorphan.
15 . The method of claim 1 , wherein the dosage form contains about 45 mg of a dextromethorphan salt.
16 . The method of claim 1 , wherein the dextromethorphan comprises a deuterium-modified dextromethorphan.
17 . The method of claim 1 , wherein the dosage form is a capsule, a tablet, or a solution.
18 . The method of claim 1 , wherein a dextromethorphan plasma level is increased as compared to administering the same amount of dextromethorphan alone.
19 . The method of claim 3 , wherein on the eighth day of the oral administration of the dosage form, the human being is converted to a poor metabolizer of dextromethorphan.
20 . The method of claim 1 , wherein the dosage form further comprises a pharmaceutically acceptable excipient.
21 . The method of claim 1 , wherein the elimination half-life of dextromethorphan increases upon orally administering the dosage form.